Nandrolone Phenylpropionate (NPP)
Fast-acting ester of nandrolone (19-nortestosterone), the same active steroid found in the better-studied decanoate. NPP delivers the classic nandrolone profile — strong lean-mass gains, joint-comfort and collagen effects, mild aromatisation and notable progestogenic activity — but with a short half-life allowing more frequent dosing and quicker clearance. Prized for its favourable anabolic-to-androgenic ratio relative to testosterone.
01 Overview
Nandrolone phenylpropionate is nandrolone esterified with phenylpropionic acid, giving a serum half-life of roughly 2-3 days versus the ~6-12 days of the decanoate. Nandrolone itself is one of the most clinically studied anabolic steroids, having been used medically for anaemia of renal failure, osteoporosis and cachexia, so the underlying pharmacology is well characterised in humans even though the phenylpropionate ester specifically is used almost entirely in bodybuilding contexts.
As a 19-nortestosterone, nandrolone is a substrate for 5-alpha reductase but is converted to the weaker dihydronandrolone, which underlies its comparatively low androgenic burden on scalp and prostate. It aromatises to a lesser extent than testosterone but its metabolites bind the progesterone receptor, so oestrogenic and progestogenic side effects (including gynaecomastia and libido/erectile problems, colloquially 'deca dick') are the defining risks. Detection windows are long owing to lipophilic metabolites stored in fat.
02 Mechanism
Binds the androgen receptor with high affinity to drive myonuclear accretion and protein synthesis; 5-alpha reduction yields the less potent dihydronandrolone, lowering androgenic load, while aromatised and progestogenic metabolites act at oestrogen and progesterone receptors.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Therapeutic | 50–100 mg/wk | IM | Historical clinical use for anaemia/osteoporosis. |
| Common | 300–400 mg/wk | IM | Split into 2-3 injections weekly due to short ester. |
| Heavy | 500–600 mg/wk | IM | Higher progestogenic and suppressive burden. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased lean muscle massNandrolone reliably increases fat-free mass and nitrogen retention in clinical and athletic settings. | +2-5 kg over 8-12 weeks | Clinical | |
| Improved joint comfortWidely reported relief of joint pain, attributed to increased collagen synthesis and water retention in connective tissue; human trial data are limited. | Anecdotal | ||
| Increased red blood cell productionStimulates erythropoiesis, historically exploited for renal anaemia; can raise haematocrit excessively. | Clinical | ||
| Increased bone mineral densityDemonstrated in osteoporosis studies of nandrolone decanoate. | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HPTA suppressionMarked suppression of endogenous testosterone and gonadotropins; nandrolone suppression is slow to recover. | Severe | Universal | Clinical | |
| Sexual dysfunction ('deca dick')Loss of libido and erectile difficulty, associated with progestogenic activity and suppressed androgens/dopaminergic tone. | Moderate | Common | Observational | |
| GynaecomastiaBreast tissue growth driven by aromatisation and progestogenic stimulation of breast tissue. | Moderate | Common | Observational | |
| Adverse lipid changesReduced HDL and unfavourable lipid shifts contributing to cardiovascular risk with prolonged use. | Moderate | Common | Clinical |